Avid Bioservices Inc (CDMO): FTM/Mojo/Entdoc/etc-etc

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	72
Posts	4827
Boards Moderated	0
Alias Born	01/24/2004

cjgaddy

Re: None

Sunday, 08/26/2012 10:26:43 AM

Sunday, August 26, 2012 10:26:43 AM

FTM/Mojo/Entdoc/etc-etc – I’m Googled till I’m blue in the face. Can ya’ll find any other currently approved 2nd-Line drugs but these? This NIH site seems the best overview source I’ve found…

Per Cancer.gov (NIH)…
Std. treatment options for Recurrent NSCLC include the following:
Chemotherapy or kinase inhibitors alone, including the following for patients who have previously received platinum chemotherapy:
• Docetaxel => MOS=6.3mos (meta-analysis of 5 trials, 865 pts)
• Pemetrexed => No diff. vs. Docetaxel (Ph.3 non-inferiority vs. Doce, 571 pts)
• Tarceva (Erlotinib) => MOS=5.3mos (TITAN* Ph.III n=424 trial - see http://tinyurl.com/8w8lo93 )
• Gefitinib => “Gefitinib does not improve OS”
• Crizotinib => very limited, only for ALK-positive pts (2-7% of pop.)
http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/page12

* "This is the first prospective head-to-head study to specifically investigate Tarceva (erlotinib) vs. systemic chemotherapy in 2nd-Line NSCLC for patients who progressed during 1st-line platinum-doublet chemotherapy.”
http://www.egfr.roche.es/TITAN/TITAN_EMCTO_Poster.pdf